HK Stock Market Move | Everest Med's early trading surged more than 5%. The patent battle for the original IgA nephropathy drug "Budenide Enteric Capsule" was successful.
Genting Hong Kong (01952) rose over 5% in early trading, as of the time of writing, it has risen by 4.75% to 35.7 Hong Kong dollars, with a turnover of 44.2498 million Hong Kong dollars.
EVEREST MED (01952) rose more than 5% in early trading, and as of the time of writing, was up 4.75% to HK$35.7 with a turnover of HK$44.298 million.
On the news front, EVEREST MED recently announced that its patent protection for the original research product Budesonide Enteric-Coated Capsules (Nifukang) has made key progress: The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's pre-litigation preservation application and ordering related generic drug companies to immediately stop infringing actions and cease online marketing. This ruling is effective immediately from the date of issuance. It is reported that in December 2025, Hainan Herui Pharmaceutical's Budesonide Enteric-Coated Capsules first generic was approved for the market.
Related Articles
Harbour Centre (00051) announced a net loss of HK$234 million for the year 2025, representing a year-on-year increase of approximately 2.34 times.
On March 4th, MNSO (09896) spent approximately $238,100 to repurchase about 55,600 shares.
"AI disrupts everything" spreads to Wall Street! Morgan Stanley (MS.US) global layoffs of 3% cover three major core departments.
Harbour Centre (00051) announced a net loss of HK$234 million for the year 2025, representing a year-on-year increase of approximately 2.34 times.
On March 4th, MNSO (09896) spent approximately $238,100 to repurchase about 55,600 shares.
"AI disrupts everything" spreads to Wall Street! Morgan Stanley (MS.US) global layoffs of 3% cover three major core departments.
RECOMMEND
